Upstream Bio (UPB) Research & Development (2023 - 2026)

Upstream Bio's Research & Development history runs 4 years deep, the most recent figure standing at $36.6 million for Q1 2026.

• On a quarterly basis, Research & Development rose 41.74% year-over-year to $36.6 million in Q1 2026; TTM through Mar 2026 was $147.6 million, a 91.48% increase from a year earlier, with the FY2025 full-year figure at $136.8 million, up 117.27% from the prior year.
• Research & Development declined to $36.6 million in Q1 2026 per UPB's latest filing, from $40.2 million in the prior quarter.
• Across five years, Research & Development topped out at $40.2 million in Q4 2025 and bottomed at $7.8 million in Q3 2023.
• The 4-year median for Research & Development is $21.8 million (2024), against an average of $23.2 million.
• Across the five-year window, Research & Development soared 169.14% in 2025 and surged 41.74% in 2026, its largest moves.
• Year by year, Research & Development stood at $11.6 million in 2023, then surged by 88.45% to $21.8 million in 2024, then soared by 84.49% to $40.2 million in 2025, then slipped by 8.97% to $36.6 million in 2026.
• Per Business Quant, the three latest UPB Research & Development figures stand at $36.6 million (Q1 2026), $40.2 million (Q4 2025), and $33.0 million (Q3 2025).